Heirs of Indian pharma companies to make large investments in high-cost drug segments

India's family-run pharmaceutical companies are undergoing a new phase, with the next generation of the companies taking on major leadership roles. According to a report by The Economic Times, this new generation is making large-scale strategic changes to pivot businesses towards complex generics, peptides, biologics, contract manufacturing, and advanced therapeutics.

These changes are not merely business shifts, but are highly expensive and long-term strategic decisions. Leading companies such as Laurus Labs, Granules India, Bharat Biotech, Sun Pharma, and Torrent Pharma are now investing to develop capabilities that require high scientific expertise. Investing in such sectors requires significant capital and takes a long time to yield results.

According to the report by The Economic Times, the main challenge in the decisions taken by this new generation is whether these heirs can convert these long-term investments into sustainable growth. Along with this, whether they can create lasting value for investors is becoming a crucial question.

In the current times, the sectors towards which pharma companies are turning are extremely complex. To achieve success in sectors like complex generics and biologics, not only financial strength but also cutting-edge research and development capabilities are indispensable. Companies like Laurus Labs and Granules India are moving in this direction, while Sun Pharma and Torrent Pharma are also focusing on this new path.

This strategic shift demonstrates that the Indian pharma industry is now moving beyond the production of generic medicines towards the production of more complex and high-value drugs. In this process, both risks and opportunities exist for investors, as the gestation period for achieving success in these sectors is long.

A generational shift is now being observed in the Indian pharmaceutical industry. Where founders had previously laid the foundational infrastructure, their incoming generation is now investing in sectors based on cutting-edge technology and science to make this infrastructure more competitive on a global scale. These investments have the potential to change the form of the Indian pharma sector in the future.

In this process, interest is also increasing in sectors such as contract manufacturing and peptides, which can provide companies with a stronger position in the global supply chain. However, acquiring the necessary scientific experts and technological readiness for all these activities is a major challenge, upon which the leadership of the companies' next generation will depend.